There’s been a lot of talk about kids having to get the vaccine for the disease triggered by the novel coronavirus.
Now, it’s been reported that a panel of U.S. health advisers endorsed kid-size doses of Pfizer’s vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11.
An FDA advisory panel voted unanimously with one abstention that the vaccine’s benefits in preventing COVID-19 in that age group outweigh any potential risks.
It’s important to note that, according to the reports coming from Fox Business, a side effect is under the spotlight.
“A heart-related side effect that’s been very rare in teens and young adults who get a much higher dose.”
The same article notes that while children are at lower risk of severe covid than older people, 5- to 11-year-olds still have faced substantial illness.
Check out the official notes mentioned by the same article:
“over 8,300 hospitalizations reported, about a third requiring intensive care, and nearly 100 deaths.”
It’s been also revealed that the dose for young children is just one-third of the Pfizer shot already recommended for everyone 12 and older. Moderna also is analyzing its vaccine for young children.
Check out more details about the effectiveness of the vaccine as revealed by the same article.
“A study of elementary schoolchildren found the Pfizer shots are almost 91% effective at preventing symptomatic infection — even though the youngsters received just a third of the dose given to teens and adults.”
Vaccinated people’s death risks are evaluated
Not too long ago, we revealed that according to a new CDC study, people who received the Pfizer-BioNTech, Moderna, or J&J vaccines are less likely to die from non-COVID-related causes.
The study was led by Stanley Xu from Kaiser Permanente Southern California and took into account people who received the Pfizer-BioNTech, Moderna, or Johnson & Johnson vaccines.
Check out more details about this issue.